68 Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence.

To investigate the impact of 68 Gallium prostate-specific membrane antigen (68 Ga-PSMA) tracers on the management of prostate cancer patients with biochemical recurrence (BCR) by systematical review and meta-analysis.